Computational design and analysis of a lung cancer vaccine targeting EGFR mutation E709G

Information from the abstract

Non-small cell lung cancer remains a leading cause of cancer-related mortality, driven significantly by specific EGFR mutations. This study utilized a quantum-inspired immunoinformatics framework to design a novel, self-adjuvanted multi-epitope vaccine specifically targeting the atypical EGFR E709G mutation. The computational methodology integrated a β-defensin adjuvant with HLA-I and HLA-II specific epitopes via optimized linkers to ensure simultaneous innate and adaptive immune engagement. Quantitative computational evaluations revealed strong predictive antigenicity (VaxiJen score = 0.8676) without inducing toxicity or allergenicity. Molecular docking simulations demonstrated highly favorable binding affinities to critical immune receptors, notably predicting robust interactions with HLA-I (HLA-A*11:01) and HLA-II (HLA-DRB1*15:01) molecules to effectively stimulate CD8+ and CD4+ T cells. To definitively validate the long-term dynamic stability and conformational reliability of the predicted complexes, extended molecular dynamics (MD) simulations were performed over a 100 ns trajectory. The rigorous computational trajectories confirmed highly stable bindings, consistent hydrogen bond networks, and favorable interaction energies within the functional grooves of both HLA-I and HLA-II receptors without disrupting the native protein folding. Furthermore, quantum-based physicochemical analyses confirmed optimal thermodynamic stability, high surface reactivity (TPSA = 2249.60 Å 2 ), and excellent solubility (LogP = − 26.02). In silico cloning into a pET-28a( +) expression vector, supported by strategic codon optimization (GC content increased to 58.65%), indicated a highly favorable profile for functional bacterial expression. These quantitative in silico findings successfully establish a high-fidelity structural template, suggesting that the designed vaccine construct possesses substantial immunotherapeutic potential and warrants further in vitro and in vivo experimental validation.

Why this record is monitored

This record has an Impact Signal of 72/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.

Related topics: vaccines and immunoinformatics approaches · Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research